Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Skyrocketed Today While the Stock Market Crashed

By Keith Speights - Mar 16, 2020 at 3:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors liked the biotech's good news about progress with its experimental coronavirus vaccine.

What happened

Shares of Moderna (MRNA 0.44%) were skyrocketing 27.9% higher as of 3:04 p.m. EDT on Monday. This huge jump came after Moderna announced that the first patient has been dosed in an early-stage clinical study for its experimental novel coronavirus vaccine mRNA-1273.

So what

Moderna's announcement was a rare piece of good news on Monday. Most stocks were slammed as worries mounted about the COVID-19 pandemic. The Federal Reserve Board announced that it was cutting interest rates to 0% and resuming its quantitative easing program. But those actions only added to investors' fears about the havoc the coronavirus outbreak will potentially wreak on the global economy.

Coronavirus vaccine bottles

Image source: Getty Images.

The first patient dosing is an important step toward determining if Moderna's messenger RNA vaccine might be effective at immunizing people against the novel coronavirus. In total, 45 healthy adults will participate in the phase 1 clinical trial that's being conducted by the National Institutes of Health (NIH). Each patient will be given two doses of Moderna's experimental vaccine, with the second dose coming 28 days after the first dose. 

Now what

While Moderna's shares vaulted higher today, the biotech stock is likely to be very volatile for a while. As the NIH proceeds with the phase 1 study, Moderna is preparing for a potential phase 2 study that it would conduct on its own. The NIH study isn't scheduled to wrap up, however, until June 2021. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$142.81 (0.44%) $0.62

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.